[HTML][HTML] Safety and Effectiveness of Molnupiravir (LAGEVRIO®) Capsules in Japanese Patients with COVID-19: Interim Report of Post-marketing Surveillance in …
M Kimata, A Watanabe, Y Yanagida… - Infectious diseases and …, 2023 - Springer
Introduction Molnupiravir is an oral antiviral drug that received special approval for
emergency use in Japan on December 24 2021 for infectious disease caused by severe …
emergency use in Japan on December 24 2021 for infectious disease caused by severe …
Safety and Effectiveness of Molnupiravir (LAGEVRIO®) Capsules in Japanese Patients with COVID-19: Interim Report of Post-marketing Surveillance in Japan.
M Kimata, A Watanabe, Y Yanagida… - … Diseases & Therapy, 2023 - search.ebscohost.com
Introduction: Molnupiravir is an oral antiviral drug that received special approval for
emergency use in Japan on December 24 2021 for infectious disease caused by severe …
emergency use in Japan on December 24 2021 for infectious disease caused by severe …
Safety and Effectiveness of Molnupiravir (LAGEVRIO®) Capsules in Japanese Patients with COVID-19: Interim Report of Post-marketing Surveillance in Japan
M Kimata, A Watanabe, Y Yanagida… - Infectious Diseases …, 2023 - search.proquest.com
Methods This survey included adult Japanese patients treated with molnupiravir. For safety,
adverse drug reactions (ADR) were assessed by physicians. Effectiveness was assessed by …
adverse drug reactions (ADR) were assessed by physicians. Effectiveness was assessed by …
Safety and Effectiveness of Molnupiravir (LAGEVRIO®) Capsules in Japanese Patients with COVID-19: Interim Report of Post-marketing Surveillance in Japan
M Kimata, A Watanabe, Y Yanagida… - Infectious diseases …, 2023 - pubmed.ncbi.nlm.nih.gov
Introduction Molnupiravir is an oral antiviral drug that received special approval for
emergency use in Japan on December 24 2021 for infectious disease caused by severe …
emergency use in Japan on December 24 2021 for infectious disease caused by severe …
Safety and Effectiveness of Molnupiravir (LAGEVRIO®) Capsules in Japanese Patients with COVID-19: Interim Report of Post-marketing Surveillance in Japan
M Kimata, A Watanabe, Y Yanagida… - Infectious Diseases …, 2023 - europepmc.org
Methods This survey included adult Japanese patients treated with molnupiravir. For safety,
adverse drug reactions (ADR) were assessed by physicians. Effectiveness was assessed by …
adverse drug reactions (ADR) were assessed by physicians. Effectiveness was assessed by …
Safety and effectiveness of molnupiravir (LAGEVRIO®) capsules in Japanese patients with COVID-19: interim report of post-marketing surveillance in Japan.
M Kimata, A Watanabe, Y Yanagida, D Kinoshita… - 2023 - cabidigitallibrary.org
Introduction: Molnupiravir is an oral antiviral drug that received special approval for
emergency use in Japan on December 24 2021 for infectious disease caused by severe …
emergency use in Japan on December 24 2021 for infectious disease caused by severe …
[HTML][HTML] Safety and Effectiveness of Molnupiravir (LAGEVRIO®) Capsules in Japanese Patients with COVID-19: Interim Report of Post-marketing Surveillance in …
M Kimata, A Watanabe, Y Yanagida… - Infectious Diseases …, 2023 - ncbi.nlm.nih.gov
Methods This survey included adult Japanese patients treated with molnupiravir. For safety,
adverse drug reactions (ADR) were assessed by physicians. Effectiveness was assessed by …
adverse drug reactions (ADR) were assessed by physicians. Effectiveness was assessed by …
Safety and Effectiveness of Molnupiravir (LAGEVRIO®) Capsules in Japanese Patients with COVID-19: Interim Report of Post-marketing Surveillance in Japan.
M Kimata, A Watanabe, Y Yanagida… - Infectious Diseases …, 2023 - europepmc.org
Methods This survey included adult Japanese patients treated with molnupiravir. For safety,
adverse drug reactions (ADR) were assessed by physicians. Effectiveness was assessed by …
adverse drug reactions (ADR) were assessed by physicians. Effectiveness was assessed by …